Conformational pH dependence of intermediate states during oligomerization of the human prion protein

Protein Science

Volumn 17, Issue 3, 2008, Pages 537-544

  Gerber, Remo ^a,c   Tahiri Alaoui, Abdessamad ^b,c   Hore, P J ^a   James, William ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Intermediates; Misfolding; Oligomer; Polymorphism; Prion protein

Indexed keywords

METHIONINE; MONOMER; OLIGOMER; PRION PROTEIN; VALINE;

ALPHA HELIX; ANALYTIC METHOD; ARTICLE; BETA SHEET; CODON; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE;

CODON; HUMANS; HYDROGEN-ION CONCENTRATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PRIONS; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 39549097936     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.073163308     Document Type: Article

References (42)

1. Ahmad, A., Millett, I.S., Doniach, S., Uversky, V.N., and Fink, A.L. 2003. Partially folded intermediates in insulin fibrillation. Biochemistry 42: 11404-11416.
2. Apetri, A.C., Maki, K., Roder, H., and Surewicz, W.K. 2006. Early intermediate in human prion protein folding as evidenced by ultrarapid mixing experiments. J. Am. Chem. Soc. 128: 11673-11678.
3. Baskakov, I.V., Legname, G., Prusiner, S.B., and Cohen, F.E. 2001. Folding of prion protein to its native α-helical conformation is under kinetic control. J. Biol. Chem. 276: 19687-19690.
4. Baskakov, I.V., Legname, G., Baldwin, M.A., Prusiner, S.B., and Cohen, F.E. 2002. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277: 21140-21148.
5. Baskakov, I., Disterer, P., Breydo, L., Shaw, M., Gill, A., James, W., and Tahiri-Alaoui, A. 2005. The presence of valine at residue 129 in human prion protein accelerates amyloid formation. FEBS Lett. 579: 2589-2596.
6. Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M., and Robinson, C.V. 2000. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9: 1960-1967.
7. Brown, P., Cervenakova, L., Goldfarb, L.G., McCombie, W.R., Rubenstein, R., Will, R.G., Pocchiari, M., Martinez-Lage, J.F., Scalici, C., Masullo, C., et al. 1994. Iatrogenic Creutzfeldt-Jakob disease: An example of the interplay between ancient genes and modern medicine. Neurology 44: 291-293.
8. Collinge, J., Palmer, M.S., and Dryden, A.J. 1991. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337: 1441-1442.
9. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. 1995. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6: 277-293.
10. Donne, D.G., Viles, J.H., Groth, D., Mehlhorn, I., James, T.L., Cohen, F.E., Prusiner, S.B., Wright, P.E., and Dyson, H.J. 1997. Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible. Proc. Natl. Acad. Sci. 94: 13452-13457.
11. Gerber, R., Tahiri-Alaoui, A., Hore, P.J., and James, W. 2007. Oligomerization of the human prion protein proceeds via a molten globule intermediate. J. Biol. Chem. 282: 6300-6307.
12. Griffith, J.S. 1967. Self-replication and scrapie. Nature 215: 1043-1044.
13. Hornemann, S. and Glockshuber, R. 1998. A scrapie-like unfolding intermediate of the prion protein domain PrP(121-231) induced by acidic pH. Proc. Natl. Acad. Sci. 95: 6010-6014.
14. Hosszu, L.L., Jackson, G.S., Trevitt, C.R., Jones, S., Batchelor, M., Bhelt, D., Prodromidou, K., Clarke, A.R., Waltho, J.P., and Collinge, J. 2004. The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt-Jakob disease by altering the structure or global stability of PrPC. J. Biol. Chem. 279: 28515-28521.
15. Jackson, G.S., Hosszu, L.L., Power, A., Hill, A.F., Kenney, J., Saibil, H., Craven, C.J., Waltho, J.P., Clarke, A.R., and Collinge, J. 1999. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283: 1935-1937.
16. Jarrett, J.T. and Lansbury Jr., P.T. 1993. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058.
17. Keller, R.L.J. 2004. The computer aided resonance assignment tutorial. Cantina Verlag, Goldau, Switzerland.
18. Kirkitadze, M.D., Condron, M.M., and Teplow, D.B. 2001. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312: 1103-1119.
19. Laplanche, J.L., Delasnerie-Laupretre, N., Brandel, J.P., Chatelain, J., Beaudry, P., Alperovitch, A., and Launay, J.M. 1994. Molecular genetics of prion diseases in France. French Research Group on Epidemiology of Human Spongiform Encephalopathies. Neurology 44: 2347-2351.
20. Legname, G., Baskakov, I.V., Nguyen, H.O., Riesner, D., Cohen, F.E., DeArmond, S.J., and Prusiner, S.B. 2004. Synthetic mammalian prions. Science 305: 673-676.
21. Maiti, N.R. and Surewicz, W.K. 2001. The role of disulfide bridge in the folding and stability of the recombinant human prion protein. J. Biol. Chem. 276: 2427-2431.
22. 2- microglobulin. Nat. Struct. Biol. 9: 326-331.
23. Morillas, M., Vanik, D.L., and Surewicz, W.K. 2001. On the mechanism of α-helix to β-sheet transition in the recombinant prion protein. Biochemistry 40: 6982-6987.
24. Novitskaya, V., Bocharova, O.V., Bronstein, I., and Baskakov, I.V. 2006. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281: 13828-13836.
25. Oesch, B., Westaway, D., Walchli, M., McKinley, M.P., Kent, S.B., Aebersold, R., Barry, R.A., Tempst, P., Teplow, D.B., Hood, L.E., et al. 1985. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40: 735-746.
26. O'Sullivan, D.B., Jones, C.E., Abdelraheim, S.R., Thompsett, A.R., Brazier, M.W., Toms, H., Brown, D.R., and Viles, J.H. 2007. NMR characterization of the pH 4 β-intermediate of the prion protein: The N-terminal half of the protein remains unstructured and retains a high degree of flexibility. Biochem. J. 401: 533-540.
27. Palmer, M.S., Dryden, A.J., Hughes, J.T., and Collinge, J. 1991. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352: 340-342.
28. Prusiner, S.B. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
29. Prusiner, S.B. 1991. Molecular biology of prion diseases. Science 252: 1515-1522.
30. Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. 95: 13363-13383.
31. Redfield, C., Schulman, B.A., Milhollen, M.A., Kim, P.S., and Dobson, C.M. 1999. α-Lactalbumin forms a compact molten globule in the absence of disulfide bonds. Nat. Struct. Biol. 6: 948-952.
32. Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., and Wuthrich, K. 1996. NMR structure of the mouse prion protein domain PrP(121-321). Nature 382: 180-182.
33. Riek, R., Hornemann, S., Wider, G., Glockshuber, R., and Wuthrich, K. 1997. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett. 413: 282-288.
34. Surewicz, W.K., Jones, E.M., and Apetri, A.C. 2006. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro. Acc. Chem. Res. 39: 654-662.
35. Swietnicki, W., Petersen, R., Gambetti, P., and Surewicz, W.K. 1997. pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). J. Biol. Chem. 272: 27517-27520.
36. Swietnicki, W., Morillas, M., Chen, S.G., Gambetti, P., and Surewicz, W.K. 2000. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 39: 424-431.
37. Tahiri-Alaoui, A. and James, W. 2005. Rapid formation of amyloid from α-monomeric recombinant human PrP in vitro. Protein Sci. 14: 942-947.
38. Tahiri-Alaoui, A., Gill, A.C., Disterer, P., and James, W. 2004. Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant: Implications for disease susceptibility to Creutzfeldt-Jakob disease. J. Biol. Chem. 279: 31390-31397.
39. Tahiri-Alaoui, A., Sim, V.L., Caughey, B., and James, W. 2006. Molecular heterosis of prion protein β-oligomers. A potential mechanism of human resistance to disease. J. Biol. Chem. 281: 34171-34178.
40. Viles, J.H., Donne, D., Kroon, G., Prusiner, S.B., Cohen, F.E., Dyson, H.J., and Wright, P.E. 2001. Local structural plasticity of the prion protein. Analysis of NMR relaxation dynamics. Biochemistry 40: 2743-2753.
41. Wroe, S.J., Pal, S., Siddique, D., Hyare, H., Macfarlane, R., Joiner, S., Linehan, J.M., Brandner, S., Wadsworth, J.D., Hewitt, P., et al. 2006. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet 368: 2061-2067.
42. Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., Lopez Garcia, F., Billeter, M., Calzolai, L., Wider, G., and Wuthrich, K. 2000. NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. 97: 145-150.